I
iVEAcare
VEAcare is developing innovative neuromodulation therapy to treat unmet clinical needs
About iVEAcare
iVEAcare is a pioneering company in the medical technology sector, focusing on the development and commercialization of next-generation neuromodulation technology platforms. These platforms are designed to treat patients suffering from chronic diseases, offering innovative solutions where traditional treatments may fall short. The company serves a diverse range of clients, including healthcare providers, hospitals, and clinics that specialize in chronic disease management. Operating in the global medical device market, iVEAcare leverages its extensive expertise in medical device innovation, research and development, manufacturing, clinical trials, and regulatory approvals to bring its products to market.
The business model of iVEAcare revolves around the development and sale of advanced neuromodulation devices. Revenue is generated through the direct sale of these devices to healthcare institutions and through partnerships with other medical technology companies. The company also invests in ongoing research and development to continually improve its product offerings and maintain a competitive edge in the market.
iVEAcare's leadership team brings decades of experience from both large medical device companies and venture capital-funded startups. This unique blend of expertise ensures a robust approach to innovation and commercialization. The company is actively hiring professionals in software, firmware, electrical engineering, quality, regulatory, and clinical roles to support its growth and development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Roseville, United States
- Employees
- 12
- Open positions
- 1
- Dealroom signal
- 71.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2024 | $28M | $110M | Hatteras Venture Partners · Vensana Capital · Treo Ventures | ↗ |
Growth signals
Latest recorded traffic for iVEAcare is 40 monthly website visits, down 76.5% over the last three months. iVEAcare's team declined 7.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Vensana Capital
Hatteras Venture Partners
Treo Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about iVEAcare on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See iVEAcare’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.